GlobalData Release: Diabetic Foot Ulcer Therapeutics Market Relying on Pipeline Therapies for Growth

Published: Jun 22, 2012

LONDON, UK (GlobalData), 22 June 2012 - The Diabetic Foot Ulcers (DFU) therapeutics market faces a turbulent few years as drug patents expire and new therapies appear on the scene, says a new report by pharmaceutical industry analysts GlobalData.

The report* outlines the problems facing the DFU therapeutics industry, including drug genericization, problematic treatments and corresponding negative public opinion.

The DFU therapeutics market, made up of the Diabetic Foot Infection (DFI) and wound healing sectors, grew from a value of $1.13 billion in 2006, to $1.53 billion in 2011. During this period the DFI portion climbed from $1 billion to $1.46 billion, but the wound healing segment had a very different fate.

The wound healing therapeutics market consists of just one product – Regranex. In 2008, the US Food and Drugs Administration (FDA) slapped a ‘black box’ warning on the product due to concerns that large quantities could increase the risk of cancer by up to five times. The US public responded with their feet, generally avoiding the medication. Accordingly, the wound healing market dropped from $126.5m in 2006, to $73.8m in 2011, dropping at a negative Compound Annual Growth Rate (CAGR) of 10.2%.

The DFI sector was also not without its woes. The three major drugs in this area all have side effect issues: Zyvox has been reported to cause myelosuppression, hematological adverse events, and optic neuropathy, whereas Invanz and Zosyn are associated with hypersensitivity reactions, and Invanz has the potential to cause seizures.

However, problems with these current treatments means there are opportunities for new drugs to push through and make an impression on the market.

The DFU therapeutics pipeline is made up of 40 molecules, 29 of which can boast first-in-class status. In the wound healing sector, the controversial Regranex is expected to be replaced by treatments such as Fragmin, Trafermin and CVBT141B. In contrast, the DFI sector will be affected by the patent expiration of Zyvox and Invanz in 2015 and 2016, respectively. This will prompt a rise in generic alternatives.

Considering these differing fortunes, GlobalData expects the DFU therapeutics market to show moderate growth, climbing from $1.53 billion in 2011 to reach $1.97 billion in 2019.

* Diabetic Foot Ulcer Therapeutics – Pipeline Assessment and Market Forecasts to 2019

This report is an essential source of information and analysis on the global Diabetic Foot Ulcers Therapeutics market. It also identifies the key trends shaping and driving the global Diabetic Foot Ulcers Therapeutics market.

This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GlobalData’s team of industry experts.


GlobalData is a leading global business intelligence provider offering advanced analytics to help clients make better, more informed decisions every day. Our research and analysis is based on the expert knowledge of over 700 qualified business analysts and 25,000 interviews conducted with industry insiders every year, enabling us to offer the most relevant, reliable and actionable strategic business intelligence available for a wide range of industries.

For more information, please contact our Press Office on +44 (0)1204 543 528 or at

Back to news